Affordable MAbs mission awarded Gates Foundation grant

Prolific Machines, a US biotech seeking to harness light to deliver unprecedented cellular control, has received a grant from the Bill and Melinda Gates Foundation to use its platform to produce more affordable monoclonal antibodies (MAbs).

The company claims that its technology has the potential to reduce MAb production costs while enhancing product quality, making these drugs more accessible and affordable for the prevention of infectious diseases like malaria, HIV, and RSV in low- and middle-income countries (LMICs).

High manufacturing costs make mAbs prohibitively expensive to much of the developing world, with access to these life-changing therapies largely limited to high-income countries.